Biosimilar use in clinical practice is determined by oncologists’ perceptions of and willingness to prescribe them. The authors investigated US oncologists’ perceptions and use of biosimilars.
Yolaine Jeune-Smith, PhD
Advertisement
Articles by Yolaine Jeune-Smith, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
2
New York Experts Push for Coordinated Obesity Care Teams
3
Grocery Assistance Benefit Linked to Fewer Diabetes Complications
4
As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning
5